NASDAQ:SMTI Sanara MedTech (SMTI) Stock Price, News & Analysis $29.49 +0.61 (+2.11%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$29.55 +0.06 (+0.20%) As of 06/6/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sanara MedTech Stock (NASDAQ:SMTI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sanara MedTech alerts:Sign Up Key Stats Today's Range$28.89▼$30.0050-Day Range$27.02▼$35.1052-Week Range$25.86▼$39.08Volume29,904 shsAverage Volume26,762 shsMarket Capitalization$262.11 millionP/E RatioN/ADividend YieldN/APrice Target$49.50Consensus RatingBuy Company OverviewSanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Read More… Sanara MedTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreSMTI MarketRank™: Sanara MedTech scored higher than 55% of companies evaluated by MarketBeat, and ranked 467th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSanara MedTech has only been the subject of 2 research reports in the past 90 days.Read more about Sanara MedTech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sanara MedTech are expected to grow in the coming year, from ($1.10) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sanara MedTech is -29.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sanara MedTech is -29.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSanara MedTech has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sanara MedTech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.05% of the float of Sanara MedTech has been sold short.Short Interest Ratio / Days to CoverSanara MedTech has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Sanara MedTech has recently decreased by 13.69%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSanara MedTech does not currently pay a dividend.Dividend GrowthSanara MedTech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.05% of the float of Sanara MedTech has been sold short.Short Interest Ratio / Days to CoverSanara MedTech has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Sanara MedTech has recently decreased by 13.69%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment1.46 News SentimentSanara MedTech has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sanara MedTech this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sanara MedTech insiders have not sold or bought any company stock.Percentage Held by Insiders54.10% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.10% of the stock of Sanara MedTech is held by institutions.Read more about Sanara MedTech's insider trading history. Receive SMTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter. Email Address SMTI Stock News HeadlinesSanara MedTech Shares Down, Investors Sought For Pilot ProgramMay 15, 2025 | marketwatch.comEarnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly becoming one of the most profitable stories of the year.June 7, 2025 | True Market Insiders (Ad)Earnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSee More Headlines SMTI Stock Analysis - Frequently Asked Questions How have SMTI shares performed this year? Sanara MedTech's stock was trading at $33.20 on January 1st, 2025. Since then, SMTI shares have decreased by 11.2% and is now trading at $29.49. View the best growth stocks for 2025 here. How were Sanara MedTech's earnings last quarter? Sanara MedTech Inc. (NASDAQ:SMTI) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.10. The business earned $23.43 million during the quarter, compared to the consensus estimate of $23.48 million. Sanara MedTech had a negative trailing twelve-month return on equity of 19.86% and a negative net margin of 10.71%. Read the conference call transcript. Who are Sanara MedTech's major shareholders? Top institutional investors of Sanara MedTech include Bank of New York Mellon Corp (0.16%), Nuveen LLC (0.12%), Goldman Sachs Group Inc. (0.07%) and Rhumbline Advisers (0.04%). Insiders that own company stock include Zachary B Fleming and Shawn M Bowman. View institutional ownership trends. How do I buy shares of Sanara MedTech? Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sanara MedTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sanara MedTech investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/14/2025Today6/07/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:SMTI CIK714256 Webwww.wndm.com Phone(817) 529-2300FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$49.50 High Stock Price Target$53.00 Low Stock Price Target$46.00 Potential Upside/Downside+67.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.30 million Net Margins-10.71% Pretax Margin-10.86% Return on Equity-19.86% Return on Assets-10.91% Debt Debt-to-Equity Ratio0.76 Current Ratio2.23 Quick Ratio2.02 Sales & Book Value Annual Sales$91.57 million Price / Sales2.86 Cash FlowN/A Price / Cash FlowN/A Book Value$5.22 per share Price / Book5.65Miscellaneous Outstanding Shares8,888,000Free Float4,012,000Market Cap$262.11 million OptionableNot Optionable Beta1.38 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:SMTI) was last updated on 6/7/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanara MedTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanara MedTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.